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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
dapsone gel is safe and effective for the treatment of acne vulgaris.
STUDY DESIGN: A review of three English language studies published in 2007. Includes two
randomized, double-blind, controlled trials and one open label, noncomparative study.
DATA SOURCES: Randomized, controlled trials comparing dapsone gel to vehicle gel control
were found using PubMed and Cochrane database.
OUTCOMES MEASURED: Success on the Global Acne Assessment Score (GAAS) and
reduction in acne lesion counts
RESULTS: The two randomized, controlled trials and the open-label noncomparative study
showed that dapsone gel was effective in the treatment of acne vulgaris. Results from the Draelos
et al and Raimer et al studies showed patients had success on the GAAS and had a reduction in
acne lesion counts. The Lucky et al study showed that patients had a reduction in acne lesions
counts. All three studies also demonstrated that dapsone gel was safe when used to treat acne
vulgaris.
CONCLUSIONS: The results of the randomized, controlled trials and open-label
noncomparative study indicate that dapsone gel for the treatment of acne vulgaris is safe and
effective.
KEY WORDS: Dapsone, acne.
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INTRODUCTION
Acne vulgaris is a common dermatologic condition that presents in adolescence and is
characterized by inflammatory lesions (papules and pustules) and non-inflammatory lesions
(comedones).1 Acne vulgaris can be chronic for some individuals but self-limiting in other cases.
Acne vulgaris tends to be more severe in males than females. Contributing factors to developing
acne include stress, genetics, and environment. Acne vulgaris may negatively impact body
image, self-esteem, and mood.2 Successful and prompt treatment of acne vulgaris can improve an
individual’s quality of life.2
In the United States, acne is the most common skin disorder affecting 40 to 50 million
individuals.3 The prevalence of acne vulgaris peaks during the middle to late teenage period and
then steadily decreases. The incidence of acne vulgaris is 30% to 60% of 10-12 year olds and
80% to 95% of 16-18-year olds that are affected.4 The direct costs associated with acne vulgaris
surpass $2.2 billion each year in the United States.5 Due to the numerous individuals affected by
acne vulgaris, this condition is commonly encountered in the scope of PA practice. It is
important to be able to correctly diagnose and treat acne vulgaris.
The pathogenesis of acne vulgaris includes many factors and the series of events in the
process of development of acne are unclear.6 Acne development is initiated during menarche
when there is increasing sebum production in the sebaceous glands.6 During menarche, the
adrenal glands, ovaries, and testes secrete androgens. This subsequently leads to an increase in
sebum production, causing hair follicles to be plugged with oil and dead skin cells that further
stimulate the development of acne.6 Other known factors that contribute to acne vulgaris are
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inflammation, follicular hyperproliferation, and Propionibacterium acnes.6 Common locations for
acne to develop include the face, neck, chest, shoulders, and back.
Acne vulgaris can be treated with a variety of medications or, simply, self-care.
Treatment of acne will help to fight bacterial infections, accelerate skin turnover, reduce
inflammation, and/or reduce oil production. Treatment options vary with each patient, depending
on the severity of acne. Some options include accutane, tretinoin, azelaic acid, benzoyl peroxide,

sulfer, salicyclic acid, resorcinol, or routine face washing with mild soap.4 Antibiotics that can be
used for acne include tetracycline, doxycycline, erythromycin, trimethoprim, and clindamycin.4
Prompt treatment is crucial because acne vulgaris can cause psychological or social dysfunction
and long-lasting deformity.
The treatment options that are listed above are all successful ways of treating acne.
Dapsone is a sulfone that has anti-inflammatory and antimicrobial properties. Dapsone has been
used orally for the treatment of acne, but is limited in use due to the potential for systemic
absorption leading to toxicity. Recently, topical dapsone gel was developed for treatment of
acne, which would offer the same antimicrobial and anti-inflammatory advantage with minimal
systemic absorption. Thus, dapsone gel offers a new treatment option for acne vulgaris.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is dapsone
gel safe and effective for the treatment of acne vulgaris?”

METHODS
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This review includes two randomized controlled trials and one open-label noncomparative study. The intervention used was dapsone gel 5%. The treatment groups receiving
dapsone gel were compared to those receiving vehicle gel control treatment. The population in
these studies consisted of men and women over the age of 12 years with acne vulgaris. The
outcomes measured were those of patient-oriented evidence. The efficacy and safety of dapsone
gel for the treatment of acne vulgaris was measured through success on the GAAS (global acne
assessment score) and reduction in acne lesion count. Safety of dapsone gel was specifically
evaluated through adverse events and physical examination findings.
The three studies in this review were researched using PubMed and Cochrane database
by the author. Keywords used in literature search were “dapsone” and “acne”. All articles were
published in English in peer-reviewed journals in 2007. Articles were selected by the author
based on their relevance and outcome to the patient. Inclusion criteria were randomized,
controlled, double-blind studies based on an outcome which was important to the patient. Studies
were excluded if they included patients under the age of 12 years old. Table 1 demonstrates the
demographics of the studies included. Statistics included in the studies were relative risk
reduction (RRR), absolute risk reduction (ARR), relative risk increase (RRI), absolute risk
increase (ARI), number needed to treat (NNT), number needed to harm (NNH), and p-values.
Both Draelos et al and Raimer et al studies were designed in a similar way. Patients were
randomly assigned dapsone gel or vehicle gel and then instructed to apply a thin layer of dapsone
or vehicle gel to the acne-affected areas for 12 weeks. In Lucky et al study, patients applied
dapsone gel to acne-involved areas for 12 months. In this study, if acne cleared up in a particular
area, treatment could be discontinued but if acne recurred, then dapsone gel was reapplied.

OUTCOMES MEASURED
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Outcomes measured were those of patient-oriented evidence that matters. Draelos et al
and Raimer et al studies assessed efficacy based on success rates on the GAAS from 0 to 4
(0=none, 1=minimal, 2=mild, 3=moderate,4=severe) and reduction from baseline in acne lesion
counts. Success on the GAAS is defined as a score of 0 or 1. Patients went through a
dermatologic examination at baseline and weeks 2, 4, 6, 8, and 12. At these visits, a Global Acne
Assessment Score was recorded. In addition, at baseline and week 12, inflammatory, noninflammatory and total lesions were counted. The Lucky et al study assessed efficacy based on
reduction of acne count lesions during a dermatological examination at baseline and months 1, 3,
6, 9, and 12.
Another outcome measured was safety of dapsone gel. This was evaluated by the adverse
events and physical examination findings. All three studies assessed patients for dryness,
peeling, and erythema. Additionally, blood was drawn for routine laboratory tests and patients
were screened for G6PD deficiency.

Table 1: Demographics & Characteristics of included studies
Study

Type

# Pts

Age

Draelos6
(2007)

Double
blind,
RCT

3010

> 12
years old

Raimer2
(2007)

Double
blind,
RCT

1306

Lucky1
(2007)

Open
label,
noncomparative

506
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Inclusion Criteria

Exclusion
Criteria
- Atleast 12 years - Severe cystic
old with a clinical acne or active/
diagnosis of acne developing
vulgaris
nodules
involving face
- Use of drugs
- 20-50
that affect acne
inflammatory
- Allergy to
lesions and 20dapsone or
100
sulfa drugs
noninflammatory - Pregnant or
lesions above the nursing women
mandibular
baseline

W/D

Intervention

503

dapsone gel
5% twice
daily or
vehicle gel
control

>12 years
old
(subgroup
presented
in this
study is
12-15
years old)

- 12 years or
older with acne
vulgaris;
- presence of 2050 inflammatory
lesions and 20100
noninflammatory
lesions above the
mandibular line
at baseline

N/A

22

dapsone gel
5% twice
daily or
vehicle gel
control

>12 years
old

- 12 years or
older with a
clinical diagnosis
of moderate to
moderately
severe acne
vulgaris defined
as at least 20
inflammatory
lesions at
baseline

- Severe cystic
acne, acne
conglobate, or
active/developi
ng nodules
- Use of drugs
that affect acne
- Allergy to
dapsone or
sulfa drugs
- Pregnant or
nursing women

166

dapsone gel
5% twice
daily

RESULTS
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This EBM review was done on two randomized controlled trials and one open-label noncomparative study. The results in these reviews were presented as dichotomous data. Data from
the studies was analyzed with the intention to treat. The inclusion criteria for all three studies
was similar. All participants were at least 12 years old with a clinical diagnosis of acne vulgaris
and had the presence of at least 20 inflammatory lesions at baseline. The Draelos et al and Lucky
et al studies had similar exclusion criteria whereas the Raimer et al study did not have an
exclusion criteria noted. Exclusion criteria included severe cystic acne, active/developing
nodules, pregnant or nursing women, allergy to dapsone or sulfa drugs, or the use of other drugs
that affect acne.
In the study done by Draelos et al, patients treated with dapsone gel had significantly
greater reduction in inflammatory, non-inflammatory, and total lesion counts from baseline to 12
weeks and achieved success on the GAAS. The relative risk reduction (RRR) was 23% and
absolute risk reduction (AAR) was 8.3%. The number needed to treat (NNT) was 13 patients.
This implies that 13 people needed to be treated with dapsone gel in order to improve acne
vulgaris in one patient. The difference in control and experimental group was a p-value less than
0.001, making it statistically significant.
In the study done by Raimer et al, dapsone gel was more effective than vehicle gel. At
week 12 patients achieved GAAS success and reduction in acne lesion counts from baseline. The
relative risk reduction (RRR) was 42% and absolute risk reduction was 11.9%. The number
needed to treat was 9 patients. Thus, 9 patients needed to be treated with dapsone gel to improve
acne vulgaris in one patient. Testing was statistically significant with a p-value less than 0.001.
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In the open-label non-comparative study done by Lucky et al, there was a reduction in

acne count lesions from baseline to 12 months with the use of dapsone gel. Inflammatory lesions
decreased the greatest by 58.2% and non-inflammatory lesions decreased by 19.5%. Total acne
lesion counts decreased by 49.0%. The test was statistically significant with a p-value of less
than 0.001. Table 2 shows the efficacy of dapsone gel in the treatment of acne vulgaris in two of
the three studies. The study done by Lucky et al is not included in Table 2 because it did not use
the GAAS score to evaluate effectiveness.

Table 2. Clinical efficacy of dapsone gel in the treatment of acne vulgaris
Study

EER
(Dapsone
gel;
Individuals
achieving
success on
GAAS)

RRR

ARR

NNT

44.2%

CER
p-value
(Vehicle
gel
control;
Individuals
achieving
success on
GAAS)
35.9%
p<0.001

Draelos
et al
(2007)
Raimer
et al
(2007)

23%

8.3%

13

40.1%

28.2%

42%

11.9%

9

p<0.001

Lucky
et al
(2007)
EER – experimental event rate, CER – control event rate, RRR – relative risk reduction,
ARR – absolute risk reduction, NNT – number needed to treat

The incidence of adverse events was also calculated by each study in regards to the safety
of dapsone gel. In the study done by Draelos et al, both dapsone gel and vehicle gel treated
groups experienced similar rates of adverse events. Patients treated with dapsone gel had an
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incidence of 58.2% and patients treated with vehicle gel had an incidence of 58.6% in terms of
adverse events. Erythema occurred in 16.3% of dapsone treated patients and 16.1% of vehicle
gel treated patients. The relative risk increase (RRI) was 1.2% and the absolute risk increase

(ARI) was 0.2%. The number needed to harm (NNH) was 500 patients. Thus, 500 patients need
to be treated with dapsone gel for one person to have erythema as an adverse event.
In the study done by Raimer et al, erythema was one of the most common adverse events
occurring at week 12. The relative risk increase (RRI) was -11.4% and absolute risk increase
(ARI) was -4.3%. The number needed to harm (NNH) was 23 patients.
The study conducted by Lucky et al found 68% of patients experienced at least one
adverse event. About 1.6% of patients experienced erythema at application site. Erythema was a
common adverse event in all three studies. Table 3 shows the incidence of erythema in patients
treated with dapsone gel versus vehicle gel treated groups.

Table 3. Incidence of erythema in dapsone gel group versus vehicle gel control group.
Study

EER
(dapsone gel)

CER
(vehicle gel
control)
16.1%

RRI

ARI

NNH

Draelos
16.3%
1.2%
0.02%
500
et al
(2007)
Raimer
33.4%
37.7%
-11.4%
-4.3%
-23
et al
(2007)
Lucky
1.6%
N/A
N/A
N/A
N/A
et al
(2007)
EER – experimental event rate, CER – control event rate, RRI – relative risk increase,
ARI – absolute risk increase, NNH – number needed to harm, N/A – not applicable

DISCUSSION
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Dapsone was shown to be effective for the treatment of acne vulgaris years ago, but was
not widespread in use due to its systemic toxicity. Dapsone has antimicrobial and antiinflammatory properties. Dapsone was known to cause adverse hemolytic reactions, more
commonly in patients with G6PD deficiency.6
The two randomized controlled trials and one open-label noncomparative study showed
that dapsone gel 5% is safe and effective for the treatment of acne vulgaris. Topical dapsone gel
has minimal systemic absorption, as noted by the studies discussed. Adverse events and routine
blood laboratory values were monitored on patients during the study, which showed similar
results between the dapsone gel treated group and vehicle gel treated group. A major concern
was patients diagnosed with G6PD deficiency, but no mean change from baseline was seen in the
hematology results.
The study done by Draelos et al showed a higher percentage of people having minimal to
no acne at the end of the treatment in patients treated with dapsone gel. In addition, those treated
with dapsone gel had greater success on the GAAS and a reduction in acne lesion counts.
Erythema was a common adverse reaction seen in both groups that were treated but declined
with the course of treatment. In the study conducted by Raimer et al, dapsone gel also caused
improvement of acne based on GAAS success and reduction in acne count lesions. Greatest
improvement was seen in inflammatory lesions. In the study done by Lucky et al, it is difficult to
assess efficacy without a control group. However, this study did assess the use of dapsone gel for
twelve months rather than only twelve weeks.
The studies in this review have some limitations. The studies done by Draelos et al and
Raimer et al were twelve weeks long, which may not be enough time to thoroughly assess
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efficacy of dapsone gel. For many patients, acne can be a chronically debilitating condition
where a longer treatment period may be needed. Also, the study done by Raimer et al only

focused on a subgroup of participants from 12 to 15 years of age. Even though acne vulgaris is
more common in young teenagers and adolescents, many older individuals are also affected and
should have been represented. In addition, the study done by Lucky et al lacked a control group.
Lack of a control group can limit findings and be inconclusive about the efficacy and safety of
dapsone.

CONCLUSION
The trials reviewed imply that dapsone gel is safe and effective for the treatment of acne
vulgaris. Patients in all three studies showed improvement in acne vulgaris when applying
topical dapsone gel. It was also suggested from these studies that dapsone gel is well-tolerated,
as it does not cause significant adverse events. Additionally, dapsone gel has a rapid onset of
action, which truly matters to the patient. Dapsone gel provides a new treatment option for
medial providers and those diagnosed with acne vulgaris. Although these studies do conclude the
use of dapsone gel is safe and effective, more trials should be done to assess the safety of using
dapsone gel over a chronic time period. Regardless of the need for additional studies, dapsone
gel is a safe and effective way of treating acne vulgaris.

References
1. Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne
vulgaris: Safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol.
2007;6(10):981-987.
2. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the
efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad
Dermatol. 2007;56(3):439.e1-439.10. doi: 10.1016/j.jaad.2006.10.005.
3. American Academy of Dermatology. Acne. American Academy of Dermatology Web
site. http://www.aad.org/media-resources/stats-and-facts/conditions/acne. Updated 2012.
Accessed September 24, 2012.
4. Knox MA. Chapter 6. Skin Diseases in Infants & Children. In: South-Paul JE, Matheny
SC, Lewis EL, eds. CURRENT Diagnosis & Treatment in Family Medicine. 3rd ed. New
York: McGraw-Hill; 2011. http://www.accessmedicine.com/content.aspx?aID=8149632.
Accessed September 29, 2012.
5. Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: Recent advances. J
Drugs Dermatol. 2009;8(7):615-618.
6. Raimer S, Maloney JM, Bourcier M, et al. Efficacy and safety of dapsone gel 5% for the
treatment of acne vulgaris in adolescents. Cutis. 2008;81(2):171-178.

